Bain Capital is in talks to acquire Mitsubishi Chemical Group’s pharmaceutical business in a potential multibillion-dollar deal, a person familiar with the matter said, a transaction that could accelerate the Japanese chemical giant’s efforts to focus on key businesses. The U.S. investment company is in the final stages of negotiations to buy the subsidiary, Mitsubishi Tanabe Pharma, for possibly more than 500 billion yen, equivalent to $3.21 billion, the person said. Bain Capital has been riding a growing wave of Japanese mergers and acquisitions in recent years.
Read the full article: Bain Capital in Talks to Buy Mitsubishi Tanabe Pharma //
Source: https://www.wsj.com/business/deals/bain-capital-in-talks-to-buy-mitsubishi-tanabe-pharma-6752fd8e